参考文献/References:
[1]李瑞华,刘波,吴英杰.miRNAs在NSCLC中的调控机制及在诊断与治疗中的作用[J].大连医科大学学报,2017,39(1):81-86.[2]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.[3]房延凤,马李杰,刘雁声,等.非小细胞肺癌E19-Del、L858R突变临床特征分析[J].中华肺部疾病杂志(电子版),2020,13(2):164-168.[4]González J,León-Mateos L,Mondelo-Macía P,et al.Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy[J].Cancer Immunol Immunother,2021,70(5):1177-1188.[5]Siegel RL,Miller KD,Fuchs HE,et al.Cancer Statistics,2021[J].CA Cancer J Clin,2021,71(1):7-33.[6]Jonna S,Subramaniam DS.Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC):an update[J].Discov Med,2019,27(148):167-170.[7]Aoki MN,Amarante MK,de Oliveira CEC,et al.Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy[J].Anticancer Agents Med Chem,2018,18(15):2070-2077.[8]丁娇娇,高天慧,赵孟阳,等.安罗替尼联合多西他赛二线治疗晚期非小细胞肺癌疗效观察[J].中华实用诊断与治疗杂志,2021,35(1):83-86.[9]Gao G,Zhou C,Huang Y,et al.Randomized phase Ⅲ study comparing the first-line chemotherapy regimens in patients with driver mutation-negative advanced non-small cell lung cancer and poor performance status complicated with chronic obstructive pulmonary disease[J].Transl Lung Cancer Res,2021,10(6):2573-2587.[10]Arrieta O,Barrón F,Ramírez-Tirado LA,et al.Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial[J].JAMA Oncol,2020,6(6):856-864.[11]Zhou C,Qin Y,Zhao W,et al.International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease[J].Transl Lung Cancer Res,2023,12(8):1661-1701.[12]Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J].Gene,2018,654:77-86.[13]Lv Y,Zhang J,Liu F,et al.Targeted therapy with anlotinib for patient with recurrent glioblastoma:A case report and literature review[J].Medicine (Baltimore),2019,98(22):e15749.[14]Chen XZ.Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China[J].JAMA Oncol,2019,5(1):116-117.[15]Mok TSK,Kim SW,Wu YL,et al.Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses[J].J Clin Oncol,2017,35(36):4027-4034.[16]饶慕圣,曹胜华,徐兴东,等.肿瘤细胞主导的血管生成拟态与肿瘤侵袭转移[J].国际外科学杂志,2019,46(1):60-63,封4.[17]Goebel J,Hoischen J,Gramsch C,et al.Tumor response assessment: comparison between unstructured free text reporting in routine clinical workflow and computer-aided evaluation based on RECIST 1.1 criteria[J].J Cancer Res Clin Oncol,2017,143(12):2527-2533.[18]Guo S,Martin MG,Tian C,et al.Evaluation of Detection Methods and Values of Circulating Vascular Endothelial Growth Factor in Lung Cancer[J].J Cancer,2018,9(7):1287-1300.[19]韩英,庞林荣,黄佳,等.安罗替尼联合多西他赛治疗晚期非小细胞肺癌的疗效分析[J].中国医刊,2020,55(11):1210-1213.[20]Wang P,Fang X,Yin T,et al.Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study[J].Front Oncol,2021,11:628124.[21]Serzan MT,Farid S,Liu SV.Drugs in development for small cell lung cancer[J].J Thorac Dis,2020,12(10):6298-6307.[22]Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβ and FGFR1[J].Gene,2018,654:77-86.[23]Gu G,Hu C,Hui K,et al.Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A[J].Int J Nanomedicine,2021,16:6329-6343.[24]Han B,Li K,Wang Q,et al.Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer:The ALTER 0303 Phase 3 Randomized Clinical Trial[J].JAMA Oncol,2018,4(11):1569-1575.[25]赵论,张浩然,石默晗,等.安罗替尼联合多西他赛二线治疗无驱动基因晚期非小细胞肺癌的临床疗效观察[J].中华全科医学,2020,18(4):537-541.[26]Daum S,Hagen H,Naismith E,et al.The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition[J].Front Cell Dev Biol,2021,8:610903.
相似文献/References:
[1]张秀芳,陈 萍.安罗替尼联合顺铂治疗晚期卵巢癌恶性腹腔积液的疗效观察[J].医学信息,2019,32(18):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
ZHANG Xiu-fang,CHEN Ping.Efficacy of Erlotinib Combined with Cisplatin in the Treatment of Advanced Ovarian Cancer with Malignant Ascites[J].Journal of Medical Information,2019,32(21):132.[doi:10.3969/j.issn.1006-1959.2019.18.044]
[2]厉 锋,鲍 乐,丁轶人,等.安罗替尼治疗晚期肝癌患者的效果[J].医学信息,2020,33(18):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
LI Feng,BAO Le,DING Yi-ren,et al.Anlotinib in the Treatment of Patients with Advanced Liver Cancer[J].Journal of Medical Information,2020,33(21):138.[doi:10.3969/j.issn.1006-1959.2020.18.045]
[3]王鹏飞,李崇慧.加味沙参麦冬汤联合安罗替尼治疗晚期非小细胞肺癌的临床观察[J].医学信息,2021,34(02):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
WANG Peng-fei,LI Chong-hui.Clinical Observation of Modified Shashen Maidong Decoction Combined with Anlotinib in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(21):167.[doi:10.3969/j.issn.1006-1959.2021.02.047]
[4]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(21):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[5]阳 芳,黄 斌,覃超群,等.血清KL-6在安罗替尼治疗的非小细胞肺癌中的表达及临床意义[J].医学信息,2023,36(01):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]
YANG Fang,HUANG Bin,QIN Chao-qun,et al.The Expression and Clinical Significance of Serum KL-6 in Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2023,36(21):90.[doi:10.3969/j.issn.1006-1959.2023.01.017]